Tirofiban with sequential dual antiplatelet therapy in mild acute ischemic stroke (TiMIS): protocol for a multicenter, randomized controlled trial - PubMed
5 hours ago
- #Tirofiban
- #Acute Ischemic Stroke
- #Antiplatelet Therapy
- TiMIS trial investigates tirofiban with sequential dual antiplatelet therapy (DAPT) in mild acute ischemic stroke (AIS).
- Aim: Compare intravenous tirofiban for 48h followed by DAPT vs. DAPT alone for 90-day functional outcomes (mRS 0-1).
- Study design: Multicenter, randomized, open-label, blinded-endpoint trial with 688 patients across 20 centers in China.
- Primary outcome: Proportion of patients with excellent functional outcomes (mRS 0-1) at 90 days.
- Secondary outcomes include early neurological deterioration (END), NIHSS score changes, safety endpoints (e.g., bleeding events).
- Target population: Adults (18-80 years) with noncardioembolic mild AIS (NIHSS ≤5) within 48h of onset.
- Potential impact: May guide antithrombotic strategies to reduce disability in mild AIS patients.